Skip to main content
main-content

Genitourinary cancers

News and opinion

21-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Race-based difference in survival with sipuleucel-T therapy confirmed

Following treatment with the autologous cellular immunotherapy sipuleucel-T for metastatic castration-resistant prostate cancer, African–American men can expect to live longer than their Caucasian counterparts, indicates an analysis of the PROCEED registry.

18-06-2019 | Renal cell carcinoma | ASCO 2019 | News

Sarcomatoid RCC patients benefit from immune checkpoint inhibitor therapy

Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.

17-06-2019 | Urothelial cancer | ASCO 2019 | News

Bevacizumab adds no value to chemotherapy for metastatic urothelial cancer

Adding bevacizumab to gemcitabine plus cisplatin chemotherapy does not improve overall survival when used as first-line therapy for metastatic urothelial carcinoma, show results of the phase III CALGB 90601 study.

14-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | News

ENZAMET supports enzalutamide use in men with metastatic CSPC

Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.

09-06-2019 | Renal cell carcinoma | ASCO 2019 | News

KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

05-06-2019 | Urothelial cancer | ASCO 2019 | News

Positive phase II findings for enfortumab vedotin in advanced urothelial cancer

Preliminary results from a pivotal trial of enfortumab vedotin, an antibody–drug conjugate targeting Nectin-4, show a “clinically meaningful” response in patients with unresectable locally advanced or metastatic urothelial cancer.

04-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Metformin addition ruled out for nondiabetic men with metastatic CRPC

The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.

03-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

Olaparib response may depend on DDR mutation type in mCRPC

The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.

02-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | News

TITAN: OS benefit seen with apalutamide in metastatic CSPC setting

Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.

01-06-2019 | Castration-resistant prostate cancer | ASCO 2019 | News

ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

30-05-2019 | Urothelial cancer | News

AE link to response shown in PD-1/PD-L1 inhibitor-treated urothelial cancer

Individuals with urothelial cancer who respond to treatment with PD-1 or PD-L1 inhibitors are more likely to report adverse events of special interest, including immune-mediated events, than nonresponders, results of a pooled analysis show.

28-05-2019 | Prostate cancer | Highlight | News

Socioeconomic factors major players in prostate cancer racial disparity

Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.

23-05-2019 | Urothelial cancer | News

Sustained nivolumab, ipilimumab activity shown in advanced urothelial cancer

Extended follow-up of patients with unresectable locally advanced or metastatic urothelial carcinoma in the CheckMate 032 trial shows sustained antitumor activity of nivolumab alone and in combination with ipilimumab.

20-05-2019 | Prostate cancer | News

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

17-05-2019 | FDA | News

USA approves first-line avelumab–axitinib for advanced RCC

Click through to read more

10-05-2019 | Bladder cancer | News

ctDNA predicts relapse and response in bladder cancer

Ultra-deep sequencing of circulating tumor DNA is highly sensitive and specific for early risk stratification in patients with bladder cancer, predicting treatment response and identifying patients with early metastatic relapse, indicate findings reported in the Journal of Clinical Oncology.

09-05-2019 | Prostate cancer | News

5α-reductase inhibitors linked to elevated prostate cancer death rates

Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.

08-05-2019 | Urothelial cancer | News

KEYNOTE-045: Pembrolizumab benefit maintained over 2 years in urothelial cancer

Patients with advanced urothelial cancer continue to derive a significant overall survival benefit with second-line pembrolizumab over chemotherapy, indicates an analysis of KEYNOTE-045 with more than 2 years of follow-up.

07-05-2019 | Immunotherapy | Highlight | News

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

02-05-2019 | Radiotherapy | News

Single HDR brachytherapy treatment effective for low-risk prostate cancer

A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.

Image Credits